Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development (Q36849332)

16 August 2017

1 reference

title

Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development (English)

1 reference

intraepithelial neoplasia

16 August 2017

1 reference

Gary J Kelloff

1

1 reference

PubMed ID

17568791

16 August 2017

Caroline C Sigman

series ordinal

2

1 reference

PubMed ID

17568791

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

Nature Reviews Cancer

1 reference

16 August 2017

7

1 reference

16 August 2017

7

1 reference

16 August 2017

508-518

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2154

16 August 2017

0 references

cites work

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue

1 reference

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

21 January 2018

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs

21 January 2018

1 reference

Celecoxib for the prevention of sporadic colorectal adenomas

21 January 2018

1 reference

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

21 January 2018

1 reference

Dichotomies in cancer research: some suggestions for a new synthesis

21 January 2018

1 reference

The US Food and Drug Administration perspective on cancer biomarker development.

21 January 2018

1 reference

Clinical biomarkers in drug discovery and development

21 January 2018

1 reference

Phases of biomarker development for early detection of cancer

21 January 2018

1 reference

Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development

21 January 2018

1 reference

New science-based endpoints to accelerate oncology drug development

21 January 2018

1 reference

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

Analysis of expression patterns: the scope of the problem, the problem of scope

21 January 2018

1 reference

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression

21 January 2018

1 reference

Imaging and oncologic drug development.

21 January 2018

1 reference

In vivo imaging of tumors with protease-activated near-infrared fluorescent probes

21 January 2018

1 reference

Spatial and spectral information in optical mammography

21 January 2018

1 reference

Risk stratification of colon carcinogenesis through enhanced backscattering spectroscopy analysis of the uninvolved colonic mucosa

21 January 2018

1 reference

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

21 January 2018

1 reference

Patient reluctance toward tamoxifen use for breast cancer primary prevention

21 January 2018

1 reference

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention

21 January 2018

1 reference

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

21 January 2018

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

Statins and cancer prevention

21 January 2018

1 reference

Cancer risk among statin users: a population-based cohort study

21 January 2018

1 reference

Statins and the risk of colorectal cancer

21 January 2018

1 reference

Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats

21 January 2018

1 reference

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride

21 January 2018

1 reference

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

21 January 2018

1 reference

Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia

21 January 2018

1 reference

Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study

21 January 2018

1 reference

A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States)

21 January 2018

1 reference

High-grade dysplasia in Barrett's esophagus. The case for esophagectomy

21 January 2018

1 reference

Radical cystectomy for bladder cancer: the case for early intervention

21 January 2018

1 reference

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

21 January 2018

1 reference

The contribution of clinical pharmacology surrogates and models to drug development--a critical appraisal

21 January 2018

1 reference

Delivery of high-quality biomarker assays

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

21 January 2018

1 reference

The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer.

21 January 2018

1 reference

Gail model and breast cancer

31 March 2020

1 reference

Cancer risk prediction models: a workshop on development, evaluation, and application

31 March 2020

1 reference

Rules of evidence for cancer molecular-marker discovery and validation

31 March 2020

1 reference

Breast cancer chemoprevention: current challenges and a look toward the future

31 March 2020

1 reference

Models for early chemoprevention trials in breast cancer

31 March 2020

1 reference

Symptom severity and QOL scales for urinary incontinence

31 March 2020

1 reference

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

31 March 2020

1 reference

Prescription of tamoxifen for breast cancer prevention by primary care physicians

31 March 2020

1 reference

Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study

31 March 2020

1 reference

Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study

31 March 2020

1 reference

The Risk of Cancer in Users of Statins

31 March 2020

1 reference

Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial

31 March 2020

1 reference

The epidemiology of breast cancer

31 March 2020

1 reference

Molecular markers of the risk of oral cancer

31 March 2020

1 reference

Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis

31 March 2020

1 reference

Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.

31 March 2020

1 reference

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

31 March 2020

1 reference

Reporting recommendations for tumor marker prognostic studies (REMARK).

31 March 2020

1 reference

Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC2154

1 reference

16 August 2017

1 reference

PubMed ID

17568791